''Jellabiya''…Annual Top Fashion Trend in Ramadan

 Female shoppers seek to buy jellabiyas during Ramadan in historic Jeddah (Photo: Adnan Mahdali)
Female shoppers seek to buy jellabiyas during Ramadan in historic Jeddah (Photo: Adnan Mahdali)
TT

''Jellabiya''…Annual Top Fashion Trend in Ramadan

 Female shoppers seek to buy jellabiyas during Ramadan in historic Jeddah (Photo: Adnan Mahdali)
Female shoppers seek to buy jellabiyas during Ramadan in historic Jeddah (Photo: Adnan Mahdali)

Fashion designers compete every year to come out with designs that keep up with the trends. Known as “jellabiya” - this traditional garment has always been the top fashion choice in the Gulf and Islamic countries during the holy month of Ramadan, which caught the attention of most international fashion designers and urged them to incorporate it in their collections as a folkloric gown highly demanded by women.

Fashion designer and stylist Manal al-Judaibi said Ramadan in Saudi Arabia has a special significance with the unique rituals and the special traditions in every region. Saudi women are used to wear the Ramadan-inspired jellabiya, which has become a common feature that adds a lot of joy to their evenings.

“The jellabiyas of Ramadan come in different designs, cuts, and fabrics. The jellabiyas worn at home are often made of light cotton fabrics for more comfort, while the formal jellabiyas are styled to suit movement and work.

"Jellabiyas designed for work and occasions are usually made from special fabrics and accessories,” Al-Judaibi explained.

The stylist stressed that the body shape should be considered while choosing the cut and design of the jellabiya, which is supposed to give a more flattering look and conceal flaws.

“The jellabiya is still highly demanded despite being a traditional, historic garment. But today, it has a more modern design,” she noted, highlighting the high turnout on jellabiyas. Al-Judaibi also explained that this high demand on this garment is driven by the stylish designs that still manage to maintain the traditional touch and attract all generations.

She also noted that the Ramadan jellabiyas come with special embroideries and prints, mostly Islamic engravings and Arabic texts in a modern style, in addition to folkloric accessories with contemporary twist, noting that the linen fabric is one of the most used in jellabiyas, while Sadu is exclusive for Ramadan.

The Saudi stylist said colors should be chosen in line with trends and seasons. Summer, for example, is know for its vivid colors, while winter calls for warm colors. The chosen color must also fit the skin tone.

Meanwhile, amid the e-shopping boom around the world, many stores in Saudi Arabia have started selling their products online to facilitate shopping, and save time, effort, and cost, which urged many women to shop jellabiyas via Instagram pages and websites that offer them a wide variety of designs and colors, and a freer experience.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”